Skip to main content
OpenTrials
Completed

NCT Number: NCT03257085

CALIBER Phase 1: A Pilot Study in Normal-weight and Overweight Adults.

Pilot study to compare the impact of following a low-carbohydrate, high-fat diet versus following a high-carbohydrates, moderate-fat diet (UK dietary guidelines) on cardiometabolic risk markers and associated behaviours in a normal-weight and overweight adult population.

Completed

Looking for future studies?

Notify Me

Key information

Age range

19 year–64 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Liverpool John Moores University

Liverpool, Merseyside, L17 6BD, United Kingdom

About this study

Cardiometabolic diseases (CMD), such as type 2 diabetes and cardiovascular disease (CVD), are globally amongst the highest contributors to morbidity and mortality with high (cost) implications to the overall economy and health care systems. A number of risk markers have been associated with CMDs, including blood serum markers, low levels of lean mass and high levels of body fat, including increased waist circumference. Dietary factors and nutritional status have long been linked with specific markers of cardiometabolic (CM) risk. The quantity and quality of dietary carbohydrates has been associated with increased serum triglycerides levels, increased body fat mass, increased waist circumference and visceral fat around the organs in particular. They also seem to increase food cravings. Whilst official dietary guidelines in the UK and elsewhere still recommend a high carbohydrate and low fat diet as standard, these recommendations have increasingly been challenged. Evidence has been mounting that very-low carbohydrate (ketogenic) and low carbohydrate diets can ameliorate CM risk factors, especially when a personalised rather than a one-size-fits-all approach is being taken. Response to carbohydrate load and adherence to dietary interventions can vary widely dependent on individual substrate and energy metabolism and insulin-resistant status.

The majority of dietary interventions with ketogenic and low-carbohydrate diets has focused on weight loss as the primary outcome in overweight and obese individuals. However, in recent years evidence has been mounting that the location and quality of adipose tissue (AT) play a more important role in manifestation of CM risk than quantity of AT alone. Detrimental health behaviours, such as low-quality diet and low levels of physical activity seem to be important contributors to this.

Further studies can provide vital insights into the links between diet, location-specific adipose tissue, CM risk factors and health-related behaviours.

Therefore this 8-weeks randomised pilot study will investigate the impact of either following a low-carbohydrate, high-fat diet versus following a high-carbohydrates, moderate-fat diet (UK dietary guidelines) on cardiometabolic risk markers and associated behaviours in a normal-weight and overweight adult population aged 19 - 64 at potential risk of CMD.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

cohort 1:

  • BMI 18.5 - 29.9kg/m2
  • Aged 19 - 64
  • White-Caucasian
  • Score of ≥4 from a combination of risk markers, including
  • Fasting glucose concentration >5.5mmol/L = 3 points
  • Waist >102cm or 40 inches = 2 points (males)
  • Waist >94 cm or 37 inches = 1 point (males)
  • Waist >88cm or 34inches = 2 points (females)
  • Waist >80 cm or 31 inches = 1 point (females)
  • Systolic blood pressure>130mmHg = 1 point
  • Diastolic BP >85mmHg = 1 point
  • HDL cholesterol concentration <1.0mmol/L = 2 points
  • Serum triglyceride concentration >1.3mmol/L = 1 point.

Exclusion criteria

cohort 1:

  • Smoker
  • Vegetarian or vegan
  • Suffering from food allergies or intolerances
  • Drinking alcohol above recommended UK government guidelines
  • Previous diagnosis of CM disease
  • Taking lipid-lowering medication
  • Taking blood pressure-lowering medication
  • Taking blood glucose-lowering medication
  • Taking dietary supplements
  • Suffering from an eating disorder
  • Current or previous renal impairment

Inclusion criteria

cohort 2:

  • BMI 18.5 - 29.9kg/m2
  • Aged 19 - 64
  • White-Caucasian

Exclusion criteria

cohort 2:

  • Smoker
  • Vegetarian or vegan
  • Suffering from food allergies or intolerances
  • Drinking alcohol above recommended UK government guidelines
  • Previous diagnosis of CM disease
  • Taking lipid-lowering medication
  • Taking blood pressure-lowering medication
  • Taking blood glucose-lowering medication
  • Taking dietary supplements
  • Suffering from an eating disorder
  • Current or previous renal impairment

Treatment and study plan

Low-carbohydrate, high-fat

Other

Participants following low-carbohydrate, high-fat diet for 8 weeks.

Other names: CALIBER LCHF

High-carbohydrate, moderate-fat

Other

Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.

Other names: CALIBER HCMF

Primary outcomes

  1. Serum lipid profile

    Time frame: 8 weeks

    Total cholesterol, HDL-C, LDL-C, non-HDL cholesterol, small-dense LDL-C and triglycerides measured in mmol/L

  2. Blood glucose

    Time frame: 8 weeks

    Measured in mmol/L

  3. Systolic and diastolic blood pressure

    Time frame: 8 weeks

    Measured in mmHg

  4. Inflammatory markers, such as CRP

    Time frame: 8 weeks

    Measured in mg/L

  5. Adiponectin

    Time frame: 8 weeks

    Measured in μg/mL

  6. Fibroblast growth factor 21 (FGF21).

    Time frame: 8 weeks

    Measured in pg/mL

  7. Tumor necrosis factor alpha and Interleukin 6

    Time frame: 8 weeks

    Measured in μg/mL

  8. Body composition - Bioelectrical impedance

    Time frame: 8 weeks

    Lean mass, fat mass and adipose tissue location and distribution

  9. Body composition - Anthropometrics

    Time frame: 8 weeks

    Waist, hip, neck, thigh and calf circumference measured in cm

Secondary outcomes

  1. Clinical traditional and emerging markers of dietary intake

    Time frame: 8 weeks

    Fibroblast growth factor 21 and serum metabolites

  2. Food cravings

    Time frame: 8 weeks

    Measured via self-reported questionnaire

  3. Satiety

    Time frame: 8 weeks

    Assessed via serum leptin levels (ng/mL)

  4. Cognition

    Time frame: 8 weeks

    Assessed via self-reported questionnaire

  5. Impact on physical activity patterns

    Time frame: 8 weeks

    Assessed via accelerometry

  6. Adherence to assigned diet

    Time frame: 8 weeks

    Measured via 4-day food diaries

  7. Adherence to dietary guidelines

    Time frame: 8 weeks

    Measured via diet quality score assessment

  8. Adherence to low-carbohydrate diet

    Time frame: 8 weeks

    Measured via blood ketones (mmol/L)

  9. Adherence to fibre recommendations

    Time frame: 8 weeks

    Measured via structured questionnaires

  10. Adherence to taking dietary supplement for low-carbohydrate, high-fat group

    Time frame: 8 weeks

    Measured via counting of number of multi-vitamin and mineral supplements consumed

  11. Experience with either low-carbohydrate, high-fat or high-carbohydrate, moderate-fat diet

    Time frame: 8 weeks

    Assessed via semi-structured interview

Sponsors and collaborators

Lead sponsor

Liverpool John Moores University

Other

Collaborators

  • Liverpool Hope University

Registry information

Official study title

CALIBER (Carbohydrates, Lipids and Biomarkers of Traditional and Emerging Cardiometabolic Risk Factors) Phase 1: A Pilot Study in Normal-weight and Overweight Adults.

Acronym: CALIBER

Important dates

Study start
2017
Primary completion
2017
Study completion
2017
First posted
Aug 22, 2017
Registry last updated
Mar 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.